“…Their progress to clinical use has been languid and hampered by several constraints, including their inhibition by physiological concentrations of salts and anionic polymers, such as glycosaminoglycans; their susceptibility to proteases and peptidases that abound at infection sites; and (largely unknown) toxicity at higher concentrations as well as their cost and issues with large-scale production [44,45]. For this reason, several mimics of HDPs have been proposed and developed to address these shortcomings, such as all-D amino acid peptides [46,47], β-peptides [48], peptoids [48,49], peptide-mimicking polymers [50], and others [51], which were to some extent successful in reproducing biological properties similar to those of HDPs. This review explicitly discusses HDP-inspired antimicrobial polymers and addresses their design principles, recent developments, limitations, and future development.…”